Astellas Pharma Inc.

21 days ago · zacks.com

Trump's MFN push expands to nine mid-sized drugmakers, bringing 26 companies under agreements covering 89% of the branded drug market.

23 days ago · defenseworld.net

Astellas Pharma (OTCMKTS:ALPMY - Get Free Report) and Kyowa Kirin (OTCMKTS:KYKOF - Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, profitability, risk and valuation. Valuation and Earnings This table compares Astellas Pharma

1 month ago · zacks.com

ASEKY, ALPMY and ATS have been added to the Zacks Rank #5 (Strong Sell) List on August 19, 2026.

1 month ago · seekingalpha.com

The portfolio outperformed the MSCI EAFE benchmark in the second quarter of 2026. Contributors include Infineon Technologies, Tokyo Electron and Recruit Holdings. Detractors include Murata Manufacturing, SoftBank Group and Astellas Pharma.

2 months ago · zacks.com

COIN, ALPMY and MUX have been added to the Zacks Rank #5 (Strong Sell) List on August 6th, 2026.

3 months ago · zacks.com

Here is how Astellas Pharma Inc. (ALPMY) and Aurinia Pharmaceuticals (AUPH) have performed compared to their sector so far this year.

3 months ago · zacks.com

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.